Table 2.
Factors associated with treatment adherence in patients.
| Characteristics | Value, n (%) | P value | |||||
|
|
Adherence (n=3780) | Nonadherence (n=695) |
|
||||
| Year | <.001 | ||||||
|
|
2013.3-2014.5 | 410 (76.9) | 123 (23.1) |
|
|||
|
|
2014.6-2015.5 | 453 (81.2) | 105 (18.8) |
|
|||
|
|
2015.6-2016.5 | 551 (83.6) | 108 (16.4) |
|
|||
|
|
2016.6-2017.5 | 677 (85.2) | 118 (14.8) |
|
|||
|
|
2017.6-2018.5 | 799 (85.5) | 136 (14.5) |
|
|||
|
|
2018.6-2019.5 | 890 (89.4) | 105 (10.6) |
|
|||
| Age (years) | <.001 | ||||||
|
|
≤50 | 1444 (86.9) | 218 (13.1) |
|
|||
|
|
50-70 | 1972 (95.6) | 332 (14.4) |
|
|||
|
|
>70 | 364 (71.5) | 145 (28.5) |
|
|||
| Educational level | <.001 | ||||||
|
|
Middle school or lower | 1386 (81.8) | 305 (18.2) |
|
|||
|
|
High school or higher | 2332 (86.1) | 377 (13.9) |
|
|||
| Marital status | .82 | ||||||
|
|
Married | 3646 (86.7) | 669 (13.3) |
|
|||
|
|
Others | 134 (83.1) | 26 (16.9) |
|
|||
| Menopausal status | .001 | ||||||
|
|
Pre | 1498 (39.6) | 230 (33.1) |
|
|||
|
|
Post | 2282 (60.4) | 465 (66.9) |
|
|||
| Benign breast disease history | .06 | ||||||
|
|
Yes | 836 (86.5) | 131 (13.5) |
|
|||
|
|
No | 2944 (83.9) | 564 (16.1) |
|
|||
| Malignant disease history | .08 | ||||||
|
|
Yes | 167 (79.9) | 42 (20.1) |
|
|||
|
|
No | 3613 (84.7) | 653 (15.3) |
|
|||
| Family history of breast cancer | .008 | ||||||
|
|
Yes | 304 (89.4) | 36 (10.6) |
|
|||
|
|
No | 3476 (84.1) | 659 (15.9) |
|
|||
| Comorbidity | .08 | ||||||
|
|
Yes | 1471 (83.3) | 295 (16.7) |
|
|||
|
|
No | 2309 (85.2) | 400 (14.8) |
|
|||
| Breast surgery | .32 | ||||||
|
|
Breast conserving | 1361 (85.2) | 236 (14.8) |
|
|||
|
|
Mastectomy | 2419 (84.1) | 459 (15.9) |
|
|||
| Axillary surgery | .001 | ||||||
|
|
SLNBa | 2526 (67.2) | 414 (60.7) |
|
|||
|
|
ALNDb | 1233 (32.8) | 268 (39.3) |
|
|||
| Tumor size (cm) | .001 | ||||||
|
|
≤2 | 2187 (86) | 355 (14) |
|
|||
|
|
>2 | 1516 (82.3) | 327 (47.9) |
|
|||
| Lymph node status | <.001 | ||||||
|
|
Negative | 2508 (86.3) | 397 (13.7) |
|
|||
|
|
Positive | 1250 (81.4) | 285 (18.6) |
|
|||
| Pathological subtype | .007 | ||||||
|
|
IDCc | 3228 (83.9) | 620 (16.1) |
|
|||
|
|
Non-IDC | 552 (88) | 75 (12) |
|
|||
| Tumor grade | <.001 | ||||||
|
|
I or II | 1938 (86) | 315 (14) |
|
|||
|
|
III | 1279 (81.3) | 295 (18.7) |
|
|||
|
|
Unknown | 563 (86.9) | 85 (13.1) |
|
|||
| LVId | .35 | ||||||
|
|
No | 3324 (84.7) | 602 (15.3) |
|
|||
|
|
Yes | 456 (83.1) | 93 (16.9) |
|
|||
| ERe status | .13 | ||||||
|
|
Negative | 933 (83) | 191 (17.9) |
|
|||
|
|
Positive | 2847 (85) | 504 (15) |
|
|||
| PRf status | .002 | ||||||
|
|
Negative | 1339 (82.2) | 290 (17.8) |
|
|||
|
|
Positive | 2441 (85.8) | 405 (14.2) |
|
|||
| HER2g status | <.001 | ||||||
|
|
Negative | 2941 (85.6) | 494 (14.4) |
|
|||
|
|
Positive | 839 (80.7) | 201 (19.3) |
|
|||
| Ki-67 | .001 | ||||||
|
|
<14% | 1219 (87.1) | 181 (12.9) |
|
|||
|
|
≥14% | 2561 (83.3) | 514 (16.7) |
|
|||
| Molecular subtype | <.001 | ||||||
|
|
Luminal-A like | 831 (90) | 92 (10) |
|
|||
|
|
Luminal-B like (HER2-negative) | 1607 (84.4) | 296 (15.6) |
|
|||
|
|
Luminal-B like (HER2-positive) | 421 (78) | 119 (22) |
|
|||
|
|
HER2 positive | 418 (83.6) | 82 (16.4) |
|
|||
|
|
Triple negative | 503 (82.6) | 106 (17.4) |
|
|||
| TNMh stage | <.001 | ||||||
|
|
Stage I | 1713 (87.7) | 241 (12.3) |
|
|||
|
|
Stage II | 1512 (82.7) | 318 (17.3) |
|
|||
|
|
Stage III | 459 (79.5) | 118 (20.5) |
|
|||
| Group according to app use | <.001 | ||||||
|
|
Pre-App cohort | 2444 (82.4) | 522 (17.6) |
|
|||
|
|
App nonused cohort | 747 (86.8) | 114 (13.2) |
|
|||
|
|
App used cohort | 589 (90.9) | 59 (9.1) |
|
|||
aSLNB: sentinel lymph node biopsy.
bALND: axillary lymph node dissection.
cIDC: invasive ductal carcinoma.
dLVI: lymphovascular invasion.
eER: estrogen receptor.
fPR: progesterone receptor.
gHER2: human epidermal growth factor receptor 2.
hTNM: tumor, lymph node, and metastasis.